Evaluating therapeutic efficacy against cancer stem cells: new challenges posed by a new paradigm.
Current measures of anticancer drug efficacy reflect bulk cell killing and are poorly suited to detect activity against cancer stem cells (CSCs), which sustain tumor growth. The CSC paradigm necessitates a reexamination of methodologies used to evaluate clinical efficacy of anticancer therapies, as well as strategies employed during preclinical drug development.
Wang
Jean C Y
JC
Division of Cell and Molecular Biology, Toronto General Research Institute, Toronto, ON M5G 1L7, Canada. jwang@uhnres.utoronto.ca
D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000378:metabolism; D016923:Cell Death; D002469:Cell Separation; D002986:Clinical Trials as Topic; D004353:Drug Evaluation, Preclinical; D006801:Humans; D018365:Neoplasm, Residual; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D014411:Neoplastic Stem Cells / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D012008:Recurrence; D012107:Research Design; D013234:Stem Cells / Q000187:drug effects; D016896:Treatment Outcome; D023041:Xenograft Model Antitumor Assays
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor